title: Cerebrospinal fluid beta2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine.
abstract: CSF levels of beta2-microglobulin (b2m), monocyte chemotactic protein-1 (MCP-1), soluble tumor necrosis factor receptors (sTNFRs), and HIV-1 RNA were determined in 16 neurologically asymptomatic HIV-1 infected patients before and 12 weeks after treatment with lamivudine plus zidovudine or stavudine. b2m levels were significantly higher in patients (1.7 mg/l) compared with controls (0.8 mg/l) (P < 0.001), and decreased to 1.1 mg/l during treatment (P = 0.001). MCP-1 levels were low, and did not change during treatment. Levels of sTNFR type I were elevated in patients (0.92 ng/ml) compared to controls (0.30 ng/ml) (P = 0.03), but did not change during treatment. Levels of sTNFR type II were below the limit of detection in most patients and controls. In conclusion, CSF levels of b2m and HIV-I RNA, but not sTNFRs or MCP-1, are candidate surrogate markers of treatment efficacy in early CNS infection.
authors.affiliation: Department of Neurology H2-214, Academic Medical Center, University of Amsterdam, Netherlands.
authors.forename: R H
authors.initials: RH
authors.lastname: Enting
authors.forename: N A
authors.initials: NA
authors.lastname: Foudraine
authors.forename: J M
authors.initials: JM
authors.lastname: Lange
authors.forename: S
authors.initials: S
authors.lastname: Jurriaans
authors.forename: T
authors.initials: T
authors.lastname: van der Poll
authors.forename: G J
authors.initials: GJ
authors.lastname: Weverling
authors.forename: P
authors.initials: P
authors.lastname: Portegies
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D018932:Chemokine CCL2 / Q000097:blood / Q000134:cerebrospinal fluid*; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000097:blood / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D015497:HIV-1; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000032:analysis* / Q000097:blood; D012995:Solubility; D018119:Stavudine / Q000627:therapeutic use; D015215:Zidovudine / Q000627:therapeutic use; D001613:beta 2-Microglobulin / Q000097:blood / Q000134:cerebrospinal fluid*
chemical_list: D019380:Anti-HIV Agents; D018932:Chemokine CCL2; D018124:Receptors, Tumor Necrosis Factor; D001613:beta 2-Microglobulin; D019259:Lamivudine; D015215:Zidovudine; D018119:Stavudine